End-stage organ failure: Will regenerative medicine keep its promise?

Fabio Triolo, Bruno Gridelli

Research output: Contribution to journalArticlepeer-review


End-stage organ failure is a major cause of death worldwide that can occur in patients of all ages and transplantation is the current standard of care for chronic end-stage disease of many organs. Despite the success of organ transplantation, it is becoming clear that there will never be enough organs made available through donation to meet the increasing demand. The past decade's rapid advancement in stem cell biology and tissue engineering generated an explosive outburst of reports that gave rise to regenerative medicine, a new field that promises to "fix" damaged organs through regeneration provided by transplanted cells, stimulation of endogenous repair mechanisms, or implantation of bioengineered tissue. Whether, and if so when, regenerative medicine will keep its promise is uncertain. As we continue to strive to find new effective solutions, alternative approaches based on the development of targeted, preventive interventions aimed at maintaining normal organ function, instead of repairing organ damage, should also be pursued.

Original languageEnglish
JournalCell Transplantation
Issue numberSUPPL. 1
Publication statusPublished - 2006


  • End-stage organ failure
  • Maintenance medicine
  • Organ shortage
  • Regenerative medicine

ASJC Scopus subject areas

  • Cell Biology
  • Transplantation


Dive into the research topics of 'End-stage organ failure: Will regenerative medicine keep its promise?'. Together they form a unique fingerprint.

Cite this